Rituximab in the treatment of TTP

Hematology

Volumn 17, Issue SUPPL. 1, 2012, Pages

  Scully, Marie ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Anti ADAMTS 13 igG; Rituximab; TTP

Indexed keywords

CD20 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADVERSE OUTCOME; ARTICLE; DISEASE CONTROL; DISEASE SEVERITY; DRUG CYTOTOXICITY; ENZYME ACTIVITY; FOLLOW UP; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MORTALITY; PATHOPHYSIOLOGY; PATIENT MONITORING; PLASMA TRANSFUSION; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN TARGETING; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; RELAPSE; REMISSION; RHEUMATOID ARTHRITIS; THERAPY EFFECT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION;

ADAM PROTEINS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 84859748651     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453312X13336169155178     Document Type: Article

References (10)

1. Scully M, Yarranton H, Liesner R, Cavenagh J, Hunt B, Benjamin S, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol. 2008;142:819-26.
2. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325:393-7.
3. Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R, et al. Efficiency of curative and prophylactic treatment with Rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood. 2005;106:1932-7.
4. Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following Rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007;136:451-61.
5. Froissart A, Buffet M, Veyradier A, Poullin P, Provot F, Malot S, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med. 2012;40:104-11.
6. Bresin E, Gastoldi S, Daina E, Belotti D, Pogliani E, Perseghin P, et al. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thromb Haemost. 2009;101:233-8.
7. Scully M, Mcdonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, et al. A phase II study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118:1746-53.
8. Mcdonald V, Liesner R, Grainger J, Gattens M, Machin SJ, Scully M. Acquired, noncongenital thrombotic thrombocytopenic purpura in children and adolescents: clinical management and the use of ADAMTS 13 assays. Blood Coagul Fibrinolysis. 2010;21:245-50.
9. Hart D, Sayer R, Miller R, Edwards S, Kelly A, Baglin T, et al. Human immunodeficiency virus associated thrombotic thrombocytopenic purpura-favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy. Br J Haematol. 2011;153:515-9.
10. Mcdonald V, Manns K, Mackie IJ, Machin SJ, Scully MA. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8:1201-8.